|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
CA2630062C
(en)
*
|
2000-07-03 |
2014-10-14 |
Bristol-Myers Squibb Company |
Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
|
|
ATE390931T1
(de)
|
2001-05-23 |
2008-04-15 |
Bristol Myers Squibb Co |
Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
|
|
CA2482042A1
(en)
*
|
2002-04-19 |
2003-10-30 |
Bristol-Myers Squibb Company |
Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
|
|
DE10232697A1
(de)
*
|
2002-07-15 |
2004-02-05 |
Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin |
Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
|
|
EP1575998A4
(en)
*
|
2002-12-23 |
2007-07-25 |
Bristol Myers Squibb Co |
PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
|
|
TWI328614B
(en)
*
|
2002-12-23 |
2010-08-11 |
Bristol Myers Squibb Co |
Product quality enhancement in mammalian cell culture processes for protein production
|
|
WO2004060911A2
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
EP1684791A4
(en)
|
2003-10-27 |
2009-07-01 |
Amgen Inc |
COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
|
|
AR058568A1
(es)
|
2005-12-20 |
2008-02-13 |
Bristol Myers Squibb Co |
Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
|
|
PT2253644E
(pt)
|
2005-12-20 |
2014-01-23 |
Bristol Myers Squibb Co |
Composições e métodos para a produção de uma composição
|
|
US7510844B2
(en)
|
2006-01-24 |
2009-03-31 |
Bristol-Myers Squibb Company |
CD86 and CD80 receptor competition assays
|
|
WO2008005290A2
(en)
|
2006-06-29 |
2008-01-10 |
The Trustees Of Columbia University In The City Of New York |
Methods for testing anti-thrombotic agents
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
US8465741B2
(en)
|
2006-12-20 |
2013-06-18 |
Mmrglobal, Inc. |
Antibodies and methods for making and using them
|
|
CA2703263C
(en)
|
2007-11-01 |
2014-03-18 |
Perseid Therapeutics Llc |
Immunosuppressive polypeptides and nucleic acids
|
|
AU2009298131B2
(en)
*
|
2008-10-02 |
2016-07-14 |
Aptevo Research And Development Llc |
CD86 antagonist multi-target binding proteins
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
WO2011113019A2
(en)
*
|
2010-03-12 |
2011-09-15 |
Abbott Biotherapeutics Corp. |
Ctla4 proteins and their uses
|
|
EP2678423A1
(en)
|
2011-02-23 |
2014-01-01 |
Amgen Inc. |
Cell culture media for uvc exposure and methods related thereto
|
|
WO2013010537A1
(en)
|
2011-07-20 |
2013-01-24 |
Aarhus Universitet |
Method of treating morphea
|
|
US9758566B2
(en)
|
2012-03-29 |
2017-09-12 |
The General Hospital Corporation |
Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
|
|
MX355234B
(es)
*
|
2012-05-11 |
2018-04-11 |
Medimmune Ltd |
Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).
|
|
US8735359B2
(en)
|
2012-05-24 |
2014-05-27 |
Orban Biotech Llc |
Combinations of modalities for the treatment of diabetes
|
|
AU2013284460A1
(en)
*
|
2012-06-27 |
2015-01-29 |
Dmnomore |
CTLA4 fusion proteins for the treatment of diabetes
|
|
US20140112958A1
(en)
|
2012-10-24 |
2014-04-24 |
Mwm Biomodels Gmbh |
Pancreatic islets of transgenic LEA29Y animals for treating diabetes
|
|
CN104740608A
(zh)
*
|
2013-12-30 |
2015-07-01 |
上海中信国健药业股份有限公司 |
可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
|
|
MX376230B
(es)
|
2014-01-13 |
2025-03-07 |
Amgen Inc |
Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
|
|
GB2523399B
(en)
|
2014-02-25 |
2019-03-13 |
Orban Tihamer |
A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
|
|
KR102391259B1
(ko)
|
2014-06-04 |
2022-04-26 |
암젠 인크 |
포유류 세포 배양물을 회수하는 방법
|
|
CA2969225C
(en)
|
2014-12-01 |
2023-08-22 |
Amgen Inc. |
Process for manipulating the level of glycan content of a glycoprotein
|
|
WO2016130734A1
(en)
|
2015-02-11 |
2016-08-18 |
Bristol-Myers Squibb Company |
Use of phenolic antioxidants in cell culture for the production of proteins
|
|
SMT202100467T1
(it)
|
2015-04-17 |
2021-09-14 |
Alpine Immune Sciences Inc |
Proteine immunomodulatorie con affinità regolabili
|
|
EP3347486A4
(en)
|
2015-09-09 |
2019-06-19 |
The Trustees of Columbia University in the City of New York |
REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
|
|
KR20180073693A
(ko)
|
2015-11-09 |
2018-07-02 |
브리스톨-마이어스 스큅 컴퍼니 |
Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법
|
|
AU2017248830B2
(en)
|
2016-04-15 |
2023-03-09 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
EP3515489B1
(en)
*
|
2016-09-19 |
2025-11-05 |
OncoC4, Inc. |
Cd80 and cd86 binding protein compositions and uses thereof
|
|
CN107987153A
(zh)
*
|
2016-10-27 |
2018-05-04 |
广东香雪精准医疗技术有限公司 |
高亲和力的可溶性pd-1分子
|
|
CN116732106A
(zh)
|
2017-04-20 |
2023-09-12 |
E开创生物技术股份有限公司 |
产生基因修改的动物的方法
|
|
EP3694870A1
(en)
*
|
2017-10-10 |
2020-08-19 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
SG11202006148UA
(en)
|
2018-01-03 |
2020-07-29 |
Alpine Immune Sciences Inc |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
CN115227824A
(zh)
*
|
2018-11-12 |
2022-10-25 |
中南大学湘雅二医院 |
免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
|
|
CN113727998A
(zh)
|
2018-11-30 |
2021-11-30 |
高山免疫科学股份有限公司 |
Cd86变体免疫调节蛋白及其用途
|
|
MX2022002337A
(es)
|
2019-08-27 |
2022-06-08 |
Tonix Pharma Ltd |
Polipéptidos de tff2 modificados.
|
|
IL309560B2
(en)
|
2019-12-06 |
2025-05-01 |
Regeneron Pharma |
Anti-VEGF protein preparations and methods for their production
|
|
MX2022013812A
(es)
|
2020-05-08 |
2022-12-15 |
Regeneron Pharma |
Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
|
|
US12202882B2
(en)
|
2020-05-08 |
2025-01-21 |
Alpine Immune Sciences, Inc. |
APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
|
|
EP4168807A1
(en)
|
2020-06-18 |
2023-04-26 |
Regeneron Pharmaceuticals, Inc. |
Heavy peptide approach to accurately measure unprocessed c-terminal lysine
|
|
CN116601279A
(zh)
|
2020-07-28 |
2023-08-15 |
思进股份有限公司 |
用于生产多肽的方法和系统
|
|
IL302830A
(en)
|
2020-11-13 |
2023-07-01 |
Egenesis Inc |
Cells, tissues, organs and animals with one or more genes that have been modified for improved survival and tolerance of a different-sex transplant
|
|
US20250040546A1
(en)
|
2021-12-16 |
2025-02-06 |
Bristol-Myers Squibb Company |
Detergent for viral inactivation
|
|
EP4486778A1
(en)
|
2022-03-02 |
2025-01-08 |
Regeneron Pharmaceuticals, Inc. |
Manufacturing process for high titer antibody
|